Precision medicine path at personalized medicine research center/endocrinology and metabolism research institute: A systematic review.

Background Precision medicine is an evolving predictive, early preventive, and treatment method that takes into account human gene heterogeneity for each individual. Personalized Medicine Research Center (PMRC) of Endocrinology and Metabolism Research Institute (EMRI) has been officially founded by the authority of the Ministry of Health and Medical Education on 18 December 2016 with the primary purpose of research, education, and dissemination of the personalized medicine approach throughout the country. In this review, we aimed to introduce the Personalized Medicine Research Center activities in the field of precision medicine since the establishment.

We systematically reviewed PubMed, Scopus, and WoS from 2016 to December 2019 to identify our relevant topics with PMRC affiliation.

After screening processes, a total of 18 studies met eligibility criteria to include in the systematic review.

Personalized medicine that interchangeably called precision medicine is a new concept in medicine, the implementation of which needs to organize some infrastructures which are physical and the required education for healthcare professionals in different countries. Similar content being viewed by others Data availability Not applicable. Abbreviations - NCDs: - Non-communicable disease - T2DM: - Type 2 diabetes mellitus - WHO: - World Health Organization - PMRC: - Personalized medicine research center - EMRI: - Endocrinology and Metabolism Research Institute - WoS: - Web of Science - SNPs: - Single nucleotide polymorphisms - CNV: - copy number variation

Aghaei Meybodi HR, Hasanzad M, Larijani B. Path to personalized medicine for Type 2 Diabetes Mellitus: reality and hope. Acta Med Iran. 2017;55(3):166–74. Hasanzad M, Sarhangi N, Aghaei Meybodi HR, Nikfar S, Khatami F, Larijani B. Precision medicine in non communicable diseases. Int J Mol Cell Med. 2019;8(2):0. Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff. 2018;37(5):694–701. Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229–34. Khatami F, Larijani B, Nikfar S, Hasanzad M, Fendereski K, Tavangar SM. Personalized treatment options for thyroid cancer: current perspectives. Pharmgenomics Pers Med. 2019;12:235–45. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364(12):1144–53. Arjmand B, Abdollahi M, Larijani B. Precision medicine: A new revolution in healthcare system. Iran Biomed J. 2017;21(5):282–3. Peykari N, Larijani B. A multi-sectoral approach to combatting non-communicable diseases: Iran’s experience. J Diabetes Metab Disord. 2019;18(2):719–20. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–88. Bennett JE, Stevens GA, Mathers CD, Bonita R, Rehm J, Kruk ME, et al. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet. 2018;392(10152):1072–88. Arjmand B, Larijani B. Personalized medicine: A new era in endocrinology. Acta Med Iran. 2017;55(3):142–3. Arjmand B, Abdollahi M, Larijani B. Study break: precision medicine: a new revolution in healthcare system. Iran Biomed J. 2017;21(5):282–3. Erfani T, Sarhangi N, Afshari M, Abbasi D, Meybodi HRA, Hasanzad M. KCNQ1 common genetic variant and type 2 diabetes mellitus risk. J Diabetes Metab Disord. 2020;19(1):47–51. Samimi H, Haghpanah V. Gut microbiome and radioiodine-refractory papillary thyroid carcinoma pathophysiology. Trends Endocrinol Metab. 2020;27(1–2):14–22. Mahdiannasser M, Haghpanah V, Damavandi E, Kabuli M, Tavangar SM, Larijani B, et al. Investigation of promoter methylation of FSCN1 gene and FSCN1 protein expression in differentiated thyroid carcinomas. Mol Biol Rep. 2020;47(3):2161–9. Khooshemehri P, Jamaldini SH, Ziaee SAM, Afshari M, Sattari M, Narouie B, et al. Genetic polymorphism of mismatch repair genes and susceptibility to prostate cancer. Urol J. 2020;17(3):271–5. Montazeri V, Ghahremani MH, Montazeri H, Hasanzad M, Safavi M, Ayati M, et al. A preliminary study of NER and MMR pathways involved in chemotherapy response in bladder transitional cell carcinoma: Impact on progression-free survival. Iran J Pharm Res. 2020;19(1):355–65. Saki N, Sarhangi N, Afshari M, Bandarian F, Aghaei Meybodi HR, Hasanzad M. MTNR1B common genetic variant is associated with type 2 diabetes mellitus risk. Gene Rep. 2020;20:100695. Afshardoost S, Sarhangi N, Afshari M, Aghaei Meybodi HR, Hasanzad M. The influence of a genetic variant in the KCNQ1 gene on type 2 diabetes mellitus development. Gene Rep. 2019;17:100529. Motamedi RK, Sarhangi N, Afshari M, Sattari M, Jamaldini SH, Samzadeh M, et al. Kallikarein-related peptidase 3 common genetic variant and the risk of prostate cancer. J Cell Biochem. 2019;120(9):14822–30. Rashidi BH, Sarhangi N, Aminimoghaddam S, Haghollahi F, Naji T, Amoli MM, et al. Association of vascular endothelial growth factor (VEGF) Gene polymorphisms and expression with the risk of endometriosis: a case-control study. Mol Biol Rep. 2019;46(3):3445–50. Hasanzad M, Larijani B. The pathway from gene therapy to genome editing: A nightmare or dream. Int J Mol Cell Med. 2019;8(2):69–70. Sarhangi N, Mohseni S, Aminimoghaddam S, Hossein Rashidi B, Haghollahi F, Qorbani M, et al. The association analysis of vascular endothelial growth factor – 2549 insertion/ deletion variant and endometriosis risk. Int J Mol Cell Med. 2019;8(Suppl1):63–8. Azizi SM, Sarhangi N, Afshari M, Abbasi D, Aghaei Meybodi HR, Hasanzad M. Association analysis of the HNF4A common genetic variants with Type 2 diabetes mellitus risk. Int J Mol Cell Med. 2019;8(Suppl1):56–62. Asgarbeik S, Mohammad Amoli M, Enayati S, Bandarian F, Nasli-Esfahani E, Forouzanfar K, et al. The role of ERRFI1 + 808T/G polymorphism in diabetic nephropathy. Int J Mol Cell Med. 2019;8(Suppl1):49–55. Mirfeizi M, Hasanzad M, Sattari M, Afshari M, Abbasi D, Ajoodani Z, et al. Association of eNOS and ACE gene polymorphisms as a genetic risk factor in gestational diabetes in Iranian women. J Diabetes Metab Disord. 2018;17(2):123–7. Sattari M, Hassanzad M, Jamaldini SH, Najafi A, Imani M, Mohammadhassani M, et al. Association between matrix metaloproteinases 2-1306C/T polymorphism and the risk of coronary artery disease in Iranian population. Pathophysiology. 2017;24(3):185–9. Author information Authors and Affiliations Contributions MH has developed the project and written the manuscript with a collaboration by NS; SHN provided some guidance to the research; and BL designed the project and revised the manuscript. All authors read and approved the final version of manuscript before submission. Corresponding authors Ethics declarations Conflict of interest The authors declare that they have no conflict of interests. Ethical approval and consent to participate Not applicable. Consent for publication Not applicable. Additional information Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Rights and permissions About this article Cite this article Sarhangi, N., Nikfar, S., Hasanzad, M. et al. Precision medicine path at personalized medicine research center/endocrinology and metabolism research institute: A systematic review. J Diabetes Metab Disord 23, 1507–1513 (2024). https://doi.org/10.1007/s40200-020-00708-9 Received: Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s40200-020-00708-9